Research in the Jiang Lab centers on the development of programmable molecular systems that can sense, respond to, and intervene in disease with exceptional precision. By integrating chemical biology, immunoengineering, nanotechnology, radiochemistry, and machine learning-assisted design, we seek to address pressing challenges in cancer detection and treatment, including limited tumor selectivity, delayed diagnosis, and the difficulty of targeting previously undruggable disease mechanisms. Our primary research directions are highlighted below.
Lysosomal targeting chimeras (LYTACs) as next-generation therapeutics
Lysosomal targeting chimeras (LYTACs) represent a transformative therapeutic modality that harnesses endogenous lysosomal trafficking pathways to selectively degrade extracellular and membrane-associated disease proteins. Our laboratory aims to develop next-generation LYTACs that integrate tumor-selective targeting, bioresponsive activation, radiotheranostic functionality, and AI-guided design to eliminate previously undruggable targets and accelerate the clinical translation of protein degradation therapies for cancer and other diseases.
Bioresponsive matrices for targeted gene regulation and radiodynamic therapy
The full therapeutic potential of CRISPR genome editing and nucleic acid medicines depends on the ability to deliver genetic cargo safely, efficiently, and with precise spatiotemporal control. Our laboratory aims to develop bioresponsive delivery systems that activate therapeutic function only in response to specific biological or external cues, enabling highly selective intervention in diseased tissues while minimizing off-target effects. These programmable systems are expected to advance precision genetic medicine and offer new opportunities to treat inherited disorders, cancer, and chronic diseases.
Radiotherapy remains a cornerstone of cancer treatment, yet its efficacy is often limited by insufficient tumor selectivity and damage to surrounding healthy tissues. Beyond targeted gene regulation, the Jiang Lab aims to construct nanoscale smart radiosensitizing platforms that amplify radiodynamic therapy with precise spatiotemporal control. Through this work, we aim to enhance the precision, potency, and safety of radiation-based cancer treatment.
Ultrasensitive Molecular Imaging for Early Diagnosis
Early detection is critical for improving disease outcomes, yet many pathological changes remain invisible to conventional imaging until advanced stages. We aim to develop ultrasensitive, activatable molecular imaging technologies that detect disease-associated biomarkers with high specificity. By integrating molecular probe engineering, NIR-II imaging, radiotracers, and AI-assisted analysis, we seek to enable early diagnosis, immune monitoring, and image-guided precision therapy.